Age dependence of brain b-amyloid deposition in Down syndrome: An [18F]florbetaben PET study

Neurology

Volumn 84, Issue 5, 2015, Pages 500-507

  Jennings, Danna ^a   Seibyl, John ^a   Sabbagh, Marwan ^b   Lai, Florence ^c   Hopkins, William ^d   Bullich, Santi ^e   Gimenez, Monica ^f   Reininger, Cornelia ^g   Putz, Barbara ^g   Stephens, Andrew ^e   Catafau, Ana M ^e   Marek, Ken ^a  

^a INSTITUTE FOR NEURODEGENERATIVE DISORDERS   (United States)

^b SUN HEALTH RESEARCH INSTITUTE   (United States)

^c MCLEAN HOSPITAL   (United States)

^d UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^e Piramal Enterprises Limited   (India)

^f HOSPITAL DEL MAR   (Spain)

^g BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; FLORBETABEN; 4-(N-METHYLAMINO)-4'-(2-(2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)STILBENE; ANILINE DERIVATIVE; FLUORINE; STILBENE DERIVATIVE;

ADULT; AGE; ARTICLE; BRAIN REGION; CLINICAL ARTICLE; COGNITION; COGNITION ASSESSMENT; CROSS-SECTIONAL STUDY; DEMENTIA; DEMENTIA SCREENING QUESTIONNAIRE FOR INDIVIDUALS WITH INTELLECTUAL DISABILITIES; DOWN SYNDROME; FEMALE; FRONTAL CORTEX; HUMAN; IMAGE ANALYSIS; IN VIVO STUDY; MALE; NEUROIMAGING; OPEN STUDY; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; BRAIN; CLINICAL TRIAL; COHORT ANALYSIS; DIAGNOSTIC USE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; SCINTISCANNING; SINGLE BLIND PROCEDURE;

ADULT; AGE FACTORS; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; BRAIN; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DOWN SYNDROME; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; SINGLE-BLIND METHOD; STILBENES;

EID: 84925843790     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001212     Document Type: Article

References (38)

1. Goldgaber D, Lerman MI, McBride WO, Saffiotti U, Gajdusek DC. Isolation, characterization, and chromosomal localization of human brain cDNA clones coding for the precursor of the amyloid of brain in Alzheimer's disease. J Neural Transm Suppl 1987;24:23-28.
2. Robakis N, Wisniewski HM, Jenkins EC, et al. Chromosome 21q21 sublocalisation of gene encoding β-amyloid peptide in cerebral vessels and neuritic (senile) plaques of people with Alzheimer disease and Down syndrome. Lancet 1987;1:384-385.
3. Tanzi RE, Gusella JF, Watkins PC, et al. Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science 1987;235: 880-884.
4. Neve RL, Finch EA, Dawes LR. Expression of the Alzheimer amyloid precursor gene transcripts in the human brain. Neuron 1988;1:669-677.
5. Beyreuther K, Pollwein P, Multhaup G, et al. Regulation and expression of Alzheimer's beta/A4 amyloid protein precursor in health disease and Down's syndrome. Ann NY Acad Sci 1993;695:91-102.
6. Sambamurti K, Greig NH, Lahiri DK. Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease. Neuromolecular Med 2002;1:1-31.
7. Rovelet-Lecrux A, Hannequin D, Raux G, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 2006;38:24-26.
8. Sleegers K, Brouwers N, Gijselinck I, et al. APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. Brain 2006;129:2977-2983.
9. Zhou ZD, Chan CH, Ma QH, Xu XH, Xiao ZC, Tan EK. The roles of amyloid precursor protein (APP) in neurogenesis: implications to pathogenesis and therapy of Alzheimer disease. Cell Adh Migr 2011;5:280-292.
10. Wisniewski KE, Wisniewski HM, Wen GY. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol 1985;17:278-282.
11. Mann DM. Alzheimer's disease and Down's syndrome. Histopathology 1988;13:125-137.
12. Mann DM. Cerebral amyloidosis, ageing and Alzheimer's disease: A contribution from studies on Down's syndrome. Neurobiol Aging 1989;10:397-399; discussion 412-414.
13. Leverenz JB, Raskind MA. Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: A regional quantitative analysis. Exp Neruol 1998;150:296-304.
14. Visser FE, Aldenkamp AP, van Huffelen AC, Kuilman M, Overweg J, van Wijk J. Prospective study of the prevalence of Alzheimer-type dementia in institutionalized individuals with Down syndrome. Am J Ment Retard 1997;101:400-412.
15. Lai F, Williams RS. A prospective study of Alzheimer disease and Down syndrome. Arch Neurol 1989;46:849-853.
16. Landt J, D'Abrera C, Holland AJ, et al. Using positron emission tomography and carbon 11-labeled Pittsburg compound B to image brain fibrillar b-amyloid in adults with Down syndrome. Arch Neurol 2011;68:890-896.
17. Handen BL, Cohen AD, Channamalappa U, et al. Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B. Alzheimers Dement 2012;8:496-501.
18. Sabbagh MN, Fleisher A, Chen K, et al. Positron emission tomography and neuropathologic estimates of fibrillar amyloid-beta in a patient with Down syndrome and Alzheimer disease. Arch Neurol 2011;68:1461-1466.
19. Barthel H, Sabri O. Florbetaben to trace amyloid-b in the Alzheimer brain by means of PET. J Alzheimers Dis 2011; 26:117-121.
20. Mathis CA, Mason NS, Lopresti BJ, Klunk WE. Development of positron emission tomography b-amyloid plaque imaging agents. Semin Nucl Med 2012;42:423-432.
21. Villemagne VL, Mulligan RS, Pejoska S, et al. Comparison of 11C-PiB and 18F-florbetaben for Ab imaging in ageing and Alzheimer's disease. Eur J Nucl Med Mol Imaging 2012;39:983-989.
22. Rowe CC, Ackerman U, Browne W, et al. Imaging of amyloid b in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008;7:129-135.
23. Barthel H, Patt M, Hammerstein E, et al. Proof of mechanism study to detect cerebral beta-amyloid plaques in patients with Alzheimer's disease (AD) using BAY 94- 9172 and PET. J Nucl Med 2008;49:33.
24. Barthel H, Luthardt J, Becker G, et al. Individualized quantification of brain b-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls. Eur J Nucl Med Mol Imaging 2011;38:1702-1714.
25. Schipke CG, Peters O, Heuser I, et al. Impact of betaamyloid specific florbetaben PET imaging on confidence in early diagnosis of Alzheimer's disease. Dement Geriatr Cogn Disord 2012;33:416-422.
26. Becker GA, Ichise M, Barthel H, et al. PET quantification of 18F-florbetaben binding to β-amyloid deposits in human brains. J Nucl Med 2013;54:723-731.
27. Deb S, Hare M, Prior L, Bhaumik S. Dementia screening questionnaire for individuals with intellectual disabilities. Br J Psychiatry 2007;190:440-444.
28. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002;5:273-289.
29. Barthel H, Gertz HJ, Dresel S, et al. Cerebral amyloid-b PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: A multi-centre phase 2 diagnostic study. Lancet Neurol 2011;10:424-435.
30. Ong K, Villemagne VL, Bahar-Fuchs A, et al. (18)F-florbetaben Ab imaging in mild cognitive impairment. Alzheimers Res Ther 2013;5:4.
31. Nelson LD, Siddarth P, Kepe V, et al. Positron emission tomography of brain b-amyloid and t levels in adults with Down syndrome. Arch Neurol 2011;68:768-774.
32. Li CM, Guo M, Salas M, et al. Cell type-specific overexpression of chromosome 21 genes in fibroblasts and fetal hearts with trisomy 21. BMC Med Genet 2006;7:24.
33. Oyama F, Cairns NJ, Shimada H, Oyama R, Titani K, Ihara Y. Down's syndrome: up-regulation of beta-amyloid protein precursor and tau mRNAs and their defective coordination. J Neurochem 1994;62:1062-1066.
34. Villemagne VL, Burnham S, Bourgeat P, et al; Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group. Amyloid b deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study. Lancet Neurol 2013;12: 357-367.
35. O'Keefe GJ, Saunder TH, Ng S, et al. Radiation dosimetry of b-amyloid tracers 11C-PiB and 18F-BAY94-9172. J Nucl Med 2009;50:309-315.
36. Cutler NR, Sramek JJ. Review of the next generation of Alzheimer's disease therapeutics: challenges for drug development. Prog Neuropsychopharmacol Biol Psychiatry 2001;25:27-57.
37. Solomon A, Mangialasche F, Richard E, et al. Advances in the prevention of Alzheimer's disease. J Int Med 2014; 275:229-250.
38. Lannfelt L, Relkin NR, Siemers ER. Amyloid-b-directed immunotherapy for Alzheimer's disease. J Intern Med 2014;27:284-295.